Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at BofA Securities
May 10, 2024 5:24 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $22.00 (from $26.00) while maintaining a Neutral rating.
The analyst comments "ACAD reported 1Q24 Daybue revenues of $75.9mn slightly missing their 1Q guidance of $76-82mn. Mgmt attributed the 1Q... More
Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
May 8, 2024 4:09 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $205.8 million versus the consensus estimate of $208.37 million.
Acadia is reiterating all of its 2024 guidance provided on February 27, 2024:
DAYBUE net product sales... More
